The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
The initiative will build and power the infrastructure required to digitize and deliver impactful AI-driven pathology solutions to patients and caregivers.
The Isambard-AI Supercomputer located at the National Composites Center in Bristol, UK, aims to be the one of the fastest 10 supercomputers in the world.